This 75-year-old man, who’s been blind since birth, suddenly regained his eyesight after using DMSO to treat sinusitis.
It cleared his sinuses “instantly,” Murray says, but what it did to his sight was “unbelievable.”
For the first time in his life, he was finally able to see color in his left eye.
And when he kept using DMSO, his vision kept improving: He could make out details and even count fingers, something he “could never do before.”
It might sound like a coincidence, but DMSO has been repeatedly shown to heal eye issues medicine still can’t solve, like blindness, macular degeneration, floaters and cataracts.
It’s Big Pharma’s worst nightmare. And it’s hiding in plain sight for just $20 a bottle. 🧵
@AmericaFirsst There is no good reason why we should bow down to the wishes of the socialst, communist, Marxist people that want to destroy America and force the people to worship the false God, Allah.
@honeymoon250 Wrong again, you jerk. People like you that lack the intelligence to know how our PRESIDENT is trying to help NORMAL AMERICANS to teach people like you that God has always Blessed America and will continue.
@honeymoon250 The United States has illegal aliens, Somalians, democrats, young protesters, and the list goes on. We have more groups looking for hand outs and proposing new governments than we can handle. It is time for the majority to form a group and start kicking ass and taking names.
How can it be that the overwhelming majority of voters want voter ID yet the Democrat Senators are able to kill the issue by going against their own constituents?
@courtneya6al The worst part of growing old is being lonely. I am 88 years young and,most of my close friends are dead. My best enjoyment is chatting on 'X'.
The quest to fundamentally reverse human aging has reached a historic milestone with the FDA officially greenlighting the first human clinical trial for a gene therapy designed to reverse biological age at the cellular level.
This groundbreaking treatment is spearheaded by Life Biosciences, a biotech company co-founded by Harvard genetics professor David Sinclair, and utilizes a technique known as partial epigenetic reprogramming. The therapy acts as a "software reset" for the body by delivering a specific cocktail of three genes that modify chemical tags on DNA to make older cells function as if they were young again.
The scientific foundation for this trial is based on staggering laboratory results where Sinclair's team used this reprogramming technique to reverse the biological age of animal cells by up to 75 percent. Rather than merely slowing aging, the therapy actively restored youthful functions, such as regenerating damaged optic nerves and curing blindness in both mice and non-human primates. These successful outcomes in animal models provided the necessary evidence to move the research into human testing.
The upcoming Phase 1 human trial will specifically target patients suffering from severe, age-related vision loss. Initial focus areas for the treatment include open-angle glaucoma and a condition often referred to as a "stroke of the eye". This targeted approach aims to validate if the cellular regeneration observed in animals can be safely replicated in humans to restore sight.
This development represents a major shift in longevity science, moving from theoretical research toward practical, clinical applications. By addressing the root cause of cellular decay rather than just treating symptoms, this gene therapy offers a new perspective on how we might manage age-related diseases in the future. While it is still in the early stages of human testing, the potential to "reset" the body's biological clock marks a new era in regenerative medicine.